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ARTICLE
Deletions at the SOX10 Gene Locus Cause Waardenburg
Syndrome Types 2 and 4
Nadege Bondurand, Florence Dastot-Le Moal, Laure Stanchina, Nathalie Collot, Viviane Baral,
Sandrine Marlin, Tania Attie-Bitach, Irina Giurgea, Laurent Skopinski, William Reardon,
Annick Toutain, Pierre Sarda, Anis Echaieb, Marilyn Lackmy-Port-Lis, Renaud Touraine,
Jeanne Amiel, Michel Goossens, and Veronique Pingault
Waardenburg syndrome (WS) is an auditory-pigmentary disorder that exhibits varying combinations of sensorineural
hearing loss and abnormal pigmentation of the hair and skin. Depending on additional symptoms, WS is classified into
four subtypes, WS1–WS4. Absence of additional features characterizes WS2. The association of facial dysmorphic features
defines WS1 and WS3, whereas the association with Hirschsprung disease (aganglionic megacolon) characterizes WS4,
also called “Waardenburg-Hirschsprung disease.” Mutations within the genes MITF and SNAI2 have been identified in
WS2, whereas mutations of EDN3, EDNRB, and SOX10 have been observed in patients with WS4. However, not all cases
are explained at the molecular level, which raises the possibility that other genes are involved or that some mutations
within the known genes are not detected by commonly used genotyping methods. We used a combination of semi-
quantitative fluorescent multiplex polymerase chain reaction and fluorescent in situ hybridization to search for SOX10
heterozygous deletions. We describe the first characterization of SOX10 deletions in patients presenting with WS4. We
also found SOX10 deletions in WS2 cases, making SOX10 a new gene of WS2. Interestingly, neurological phenotypes
reminiscent of that observed in WS4 (PCWH syndrome [peripheral demyelinating neuropathy, central dysmyelinating
leukodystrophy, WS, and Hirschsprung disease]) were observed in some WS2-affected patients with SOX10 deletions.
This study further characterizes the molecular complexity and the close relationship that links the different subtypes of
WS.
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During development, the pluripotent neural-crest cells mi-
grate from the neural tube throughout the embryo along
several pathways and give rise to different cell types, in-
cluding glia and neurons of the peripheral nervous system,
enteric neurons and glia, some of the craniofacial skeletal
tissue, and melanocytes of the skin and inner ear.1 Defects
in neural-crest development are a significant cause of
human disease. The term “neurocristopathies” collectively
refers to these neural-crest disorders, one of which is Waar-
denburg syndrome (WS).2–4 The association of hearing loss
and pigmentary abnormalities (e.g., heterochromia irides,
white skin patches, and white forelock) characteristic of
this syndrome results from an abnormal proliferation, sur-
vival, migration, or differentiation of neural-crest–derived
melanocytes.3 Several subtypes of WS were defined on the
basis of the presence of additional symptoms.
Type I WS (WS1 [MIM 193500]) refers to the first cases
described by Waardenburg.5 Additional symptoms are dys-
topia canthorum and broad nasal root. Nearly all patients
present with heterozygous mutations of PAX3 (encoding
paired box gene 3 [PAX3], a member of the paired box
family of transcription factors). Type III WS (WS3 [MIM
148820]), or Klein-Waardenburg syndrome, is an extreme
presentation of type I WS, with hypoplasia of limb mus-
cles, and is also caused by heterozygous or homozygous
mutations of PAX3.3,6,7
Type II WS (WS2 [MIM 193510]) is characterized by
deafness and pigmentation defects without additional fea-
tures. Heterozygous mutations in the MITF gene (encod-
ing microphthalmia-associated transcription factor [MITF],
a basic helix-loop-helix transcription factor) have been
identified in ∼15% of cases.3,8 Homozygous deletions of
the SNAI2 gene (encoding snail homolog 2, a C2H2-type
zinc-finger transcription factor) have also been described
in two patients.9 Therefore, 85% of WS2 cases are still
unexplained at the molecular level.
Type IV WS (WS4 [MIM 277580]), also called “Shah-
Waardenburg syndrome” or “Waardenburg-Hirschsprung
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disease,” combines pigmentation defects, deafness, and
Hirschsprung disease.10 Mutations in EDNRB, which en-
codes the endothelin B receptor (a G-protein–coupledtrans-
membrane receptor), and EDN3, which encodes its ligand,
endothelin-3, have been described. Homozygous (most
frequently) or heterozygous mutations are found in pro-
bands with WS4, whereas heterozygous family members
occasionally present with some of the features.4,11–17
Dominant mutations of SOX10 have also been identi-
fied in WS4.18 SOX10 is a key transcription factor of neu-
ral-crest development. It is crucial for the survival and
maintenance of pluripotency of migrating neural-crest
progenitors19,20 and also influences fate decisions and dif-
ferentiation at later stages.21–25 SOX10 belongs to the SOX
family of transcription factors and is closely related to
SOX8 and SOX9, the latter of which is involved in cam-
pomelic dysplasia.21,23,25–27 All SOX proteins contain a
DNA-binding motif known as the high-mobility group
(HMG) domain. In addition, SOX10, like SOX8 and SOX9,
contains a transactivation domain located in the C-ter-
minal part of the protein and a dimerization domain im-
mediately preceding the HMG domain.21,22,28,29 Functional
studies revealed the importance of these domains for mo-
nomeric or dimeric DNA binding and transactivation of
natural target genes.21,22 Among them are genes/factors
crucial for the specification and differentiation of mela-
nocytes or enteric nervous-system development, such as
MITF/Mitf, TRYP2/Dct (encoding dopachrome tautomer-
ase), tyrosinase, EDNRB, and the RET protooncogene.30–41
SOX10 targets also include genes important for glia de-
velopment and identity, such as MPZ (encoding myelin
protein zero [P0]), MBP (encoding myelin basic protein),
and GJB1 (encoding the gap-junction protein connexin
32).29,42–46
The SOX10 mutations characterized so far are mostly
truncating mutations—that is, nonsense and frameshift
mutations and one splice mutation—which most often
remove all or part of the transactivation domain.18,47–58 An
insertion of 2 aa and an amino acid substitution in the
HMG domain, as well as two mutations of the stop codon
supposed to give rise to elongated SOX10 protein, have
also been described.18,48,49,53 Unexpectedly, some of the pa-
tients with SOX10 mutations present with chronic in-
testinal pseudo-obstruction instead of Hirschsprung dis-
ease51,55 and/or with neurological features, either periph-
eral demyelinating neuropathy or central neuropathy or
both, which leads to a syndrome called “PCWH” (periph-
eral demyelinating neuropathy, central dysmyelinating
leukodystrophy, WS, and Hirschsprung disease).57 This
more severe disease is mostly caused by mutations in the
last coding exon of SOX10 and has been proposed to occur
when the mutant mRNAs escape the nonsense-mediated
mRNA decay (NMD) pathway.57
However, some WS4 cases remain unexplained at the
molecular level, which suggests that other genes may be
involved or that some mutations within the known genes
are not detected by the methods commonly used for ge-
notyping. Therefore, we used semiquantitative fluores-
cent multiplex PCR (QMF-PCR) to search for heterozy-
gous SOX10 deletions. Here, we describe the first char-
acterization of SOX10 deletions in patients presenting
with WS4. In light of the phenotypic variability observed
among patients with SOX10 point mutations, we also
searched for SOX10 deletions in unexplained cases of WS2
and found several, making SOX10 a new gene of WS2.
Subjects and Methods
Subjects
We investigated a total of 30 patients presenting with the classic
form of WS4 or PCWH; 29 were found to be negative for EDN3,
EDNRB, and SOX10 point mutations, and 1 was found to be hemi-
zygous for a SOX10 point variation within the course of this work.
Our study also included 30 WS2-affected patients without MITF
mutations. Clinical information and DNA samples were obtained
with informed consent in accordance with French law for genetic
testing. The main clinical findings in patients presenting with
SOX10 gene deletions are summarized in table 1. Detailed clinical
descriptions of the patients presenting with SOX10 gene deletions
are as follows.
Patient 1, a 1-year-old boy, was born at term to unrelated par-
ents after unremarkable pregnancy and delivery. At age 48 h, he
presented with clinical signs of meconium plug syndrome caused
by short-segment Hirschsprung disease. Bilateral absence of re-
sponses to brain stem auditory-evoked potential strongly sug-
gested bilateral deafness. He also had hair and skin hypopigmen-
tation and bilateral cryptorchidism.
Patient 2, a 13-year-old boy, was born at term to unrelated
parents after a pregnancy complicated by gestational diabetes. He
has two healthy sisters. He had delayed psychomotor develop-
ment, hair and skin hypopigmentation, sapphire blue eyes, and
short-segment Hirschsprung disease that required a surgical pro-
cedure at age 15 mo. Nine months later, he had implantation of
a unilateral cochlear device for profound bilateral congenital
deafness. In spite of good perceptual results, he had speech and
sign-language impairment because of dyspraxia. He had mild
mental retardation, anosmia, hypermetropia, and dental-enamel
abnormalities.
Patient 3, a 36-year-old man, was born at term to unrelated
parents after unremarkable pregnancy and delivery. In the neo-
natal period, he had axial hypotonia and delayed psychomotor
development; he could hold his head up at age 1 year, sit alone
at age 3 years, and walk at age 4–5 years. He had hair and skin
hypopigmentation, sapphire blue eyes, short-segment Hirsch-
sprung disease, and profound bilateral congenital deafness, for
which he had implantation of a unilateral cochlear device at age
32 years. Temporal bone CT scan revealed a bilateral vestibular
malformation and hypoplasia of the external and posterior sem-
icircular canals. He also presented with anosmia, bilateral crypt-
orchidism, hypogonadotropic hypogonadism, and bone-age and
pubertal growth delay. He now has mild mental retardation with
marked abstraction difficulties.
Patient 4, a 9-year-old boy, was born at term to unrelated par-
ents after unremarkable pregnancy and delivery. He began to walk
at age 21 mo. A bilateral sensorineural hearing impairment was
discovered at age 6 mo and progressed to profound deafness. A
cochlear implantation was performed with success, in terms of
his comprehension and language skills. Temporal bone CT scan
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Table 2. QMF-PCR Primer Sequences
Primer
Primer Sequence
(5′r3′)
Reaction
Mix
PCR
Product
Size
(bp) Gene Position
GenBank
Accession
NumberForward Reverse
Reference:
DSCR1 GCGACGAGGACGCATTCCAA GTCCTTGTGCGATCACCACA 1 and 2 238 DSCR1 exon 4 NC_000021.7
F9 AAATGATGCTGTTACTGTCTA GAAGTTTCAGATACAGATTTTC 1 and 2 214 F9 exon 5 NC_000023.9
SOX10:
P5 GGCCAGGCGAGCTGGGCAAGGTC GAATCCACCCGAAGCTAGAG 1 341 SOX10 exon 3 NC_000022.9
P6 GGAGTGCTCTGGCATTCACG CTTGCCCCACCCTCAGCTCT 1 366 SOX10 exon 4 NC_000022.9
P7 GGAAGTTCACGTGCGCCCAC GCGGCAGGTACTGGTCCAAC 1 286 SOX10 exon 5 NC_000022.9
P8 CCACACTACACCGACCAGCC GGGTGGTGGCGACAGGGC 1 326 SOX10 exon 5 NC_000022.9
External markers:
P9 GATGACGTTTCTAGGTGG TGTTCCTAAGGATCTGTAGG 1 309 POLR2F exon 4 NC_000022.9
P1 GAGGAGGGAGTTTGGGTGGGTGG GCACAGGATGGGACGGGTTGAGA 2 310 54694/55003 NC_000022.9
P2 TGGGAACAATGTCAACGTCG CAGAAGGCCTCCTCCAATGA 2 330 32490/32819 NC_000022.9
P3 TACCAGGGCGGGCTCCTGTA GCCCCTGTTCCTTCCAGACTCCC 2 363 14793/15155 NC_000022.9
P4 ACACGACGGCAGATGCTCGT CCTCGGAGCCCAGTGAATTA 2 335 2116/2450 NC_000022.9
NOTE.—GenBank accession numbers, positions, sequences, and expected PCR product sizes are given for primers P1–P9. Positions of primers
P1–P4 are given with the A of the SOX10 ATG numbered as 1. NCBI build 36.2 was used.
revealed a symmetrical bilateral vestibular malformation with di-
latation of the vestibule, hypoplasia, and dilatation of the exter-
nal and posterior semicircular canals. He presented with hypo-
pigmentation of the skin, irides, and retina. He had no history
of constipation, and his neurological development was normal.
His brother presented with similar clinical symptoms. No other
cases of hearing defect or pigmentation anomalies were observed
in the family.
Patient 5, an 8-year-old boy, was born at term to unrelated
parents after unremarkable pregnancy and delivery. He began to
walk at age 20 mo. A profound bilateral sensorineural hearing
impairment was diagnosed at age 5 mo. Temporal bone CT scan
did not reveal any malformation of the inner ears. He presented
with skin depigmentation and hypoplastic irides. He had no his-
tory of constipation, and his neurological development was nor-
mal. His mother presented with a bilateral severe sensorineural
prelingual hearing impairment. She was born with a frontal white
forelock and heterochromia (i.e., one green iris and one hypo-
plastic iris).
Patient 6, an 8-year-old boy, is the third child of a nonconsan-
guineous couple from the French Caribbean islands. At age 9 mo,
a severe bilateral sensorineural hearing impairment was diag-
nosed and progressed to bilateral profound deafness by age 8
years. He presented a white frontal forelock at birth and heter-
ochromia irides (i.e., one black and one hypoplastic) but has no
skin depigmentation. He began walking at age 17 mo and has no
history of severe constipation or neurological anomaly.
Patient 7, a 23-year-old man, was born at term to unrelated
parents after unremarkable pregnancy and delivery. He presented
with a white frontal forelock (now disappeared), skin hypopig-
mentation, sapphire blue eyes, pectus excavatum, and statural
growth on the 3rd percentile. He has no constipation problems.
In addition, this patient has severe autism and developmental
delay (he started to walk at age 3 years, is not toilet trained, and
has little autonomy). Brain CT scan was normal. Bilateral sen-
sorineural deafness was diagnosed at age 9 mo, and he had a
cochlear implant until age 13 years. However, because of severe
behavioral problems, hearing loss has not been evaluated since
age 13 years.
Patient 8 was born at term to unrelated parents after unre-
markable pregnancy and delivery. She presented with severe con-
genital heart disease associating double-outlet right ventricle,
transposition of the great arteries, pulmonary atresia, patent duc-
tus arteriosus, ventricular septal defect, and atrial septal defect.
A white forelock and a duplication of the thumb on the left side
were noted. At age 10 mo, she presented obvious evidence of
deafness, medial flare of the eyebrows, strabismus, and general
hypotonia. Brain magnetic resonance imaging scan at age 14 mo
showed delayed myelination. Specific evaluation of the skin on
Wood’s lamp revealed multiple hypopigmented areas. She had
no history of constipation. Heart surgery had been partially suc-
cessful, but episodes of unexplained bradychardia and peripheral
cyanosis were observed, and the patient died at age 19 mo.
QMF-PCR
QMF-PCR has been shown to be a sensitive method for the de-
tection of gene-dosage anomalies and has been successfully used
in our laboratory to characterize deletions and duplications
within several genes.59,60 We adapted the protocol described
elsewhere,61,59 to screen for SOX10 gene deletions. In brief, the
three coding exons of SOX10, exon 4 of POLR2F, and four regions
located 5′ of SOX10 were amplified in two multiplex reactions.
The beginning of exon 3 and the middle of the exon 5 coding
sequences are not covered by the amplicons; however, a deletion
restricted to one of these regions would have been found during
the point-mutation screening. Noncoding regions of SOX10 were
not studied. GenBank accession numbers, positions, sequences
of the primers, and PCR product sizes are shown in table 2. In
each set, two controls were used: DSCR1, located on chromosome
21, and F9, located on chromosome X (see reference genes in
table 2). The reverse primers were labeled with the fluorescent
phosphoramidite 6-FAM dye. Amplifications were performed in
duplicates in 25-ml reactions with use of the QIAGEN Multiplex
PCR kit (Qiagen), with 75 ng of genomic DNA, a mix of primers
(concentration range 0.1–1 mM), and 5% dimethyl sulfoxide
(DMSO). The reaction started with an initial denaturation for 15
min at 95C, followed by 22 cycles at 95C for 30 s, at 55C
(multiplex reaction mix 1) or 58C (multiplex reaction mix 2) for
30 s, and at 72C for 45 s with an increment of 3 s per cycle, and
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Table 3. DQ Values from QMF-PCR Performed with Mix 1
DNA
Sample
SOX10 5′
Region S4
(P4)
SOX10
POLR2F
Exon 4
(P9)
Exon 3
(P5)
Exon 4
(P6)
Exon 5
(P7)
Exon 5
(P8)
Subject 1 1.07 1.02 1.12 1.02 1.02 1.00
Subject 2 1.02 1.08 1.03 .97 .93 .94
Patient 1 1.00 1.02 .96 .47 1.10 .86
Patient 2 .46 .50 .46 .51 .49 .45
Patient 3 .47 .47 .48 .51 .51 .51
Patient 4 1.20 .58 .90 1.17 1.20 .83
Patient 5 .90 1.10 .56 1.08 .96 .99
Patient 6 .52 .54 .48 .52 .56 .43
Patient 7 .56 .56 .45 .54 .57 .48
Patient 8 .51 .46 .53 .50 .49 .50
NOTE.—The analysis is based on the comparison of the peak height from the tested DNA (two
patients without deletion, called subjects 1 and 2, and patients 1–8) to control DNA samples.
The copy-number change for each amplicon was calculated using the peak value normalized to
the peak value of DSCR1 exon 4. DQ values !0.6 are indicated in bold.
a final extension for 10 min at 72C. Then, 3 ml of the purified
PCR products were processed as described elsewhere.59 Two con-
trol DNA samples (male and female) were included in each ex-
periment. Results were analyzed by superimposing fluorescent
profiles of tested patients and controls and by calculating dosage
quotient (DQ).59 DQ values !0.6 were considered as indicating
potential deletions. Table 3 summarizes examples of DQ values
obtained.
Molecular Characterization of Rearrangements
When QMF-PCR revealed a short-size deletion (only one exon
removed), the genomic region encompassing the deletion break-
point was amplified either by classic or long-range PCR with the
use of Dynazyme Ext DNA polymerase (Ozyme) or the Expand
Long Template PCR system (Roche Diagnosis), respectively. The
resulting PCR fragments were cloned into the TOPO-TA cloning
kit dual promoter or the TOPO-XL PCR cloning kit (Invitrogen)
and were sequenced. Bioinformatics analysis was performed to
predict the functional consequences of intragenic deletions, with
the use of Netgene2 (neural-network predictions of splice sites in
humans) and HMMgene (gene-structure prediction) software.
In the case of whole SOX10 gene deletions, FISH was used to
confirm the QMF-PCR results. Molecular cytogenetic studies were
performed on chromosomes prepared from cultured fibroblasts
(patient 8) or peripheral blood cells. Metaphase chromosomes
were obtained according to standard techniques. FISH was per-
formed as described elsewhere.62 PAC and BAC clones used in
FISH experiments were provided by the BACPAC Resources Center
(Children’s Hospital Oakland, Oakland, CA) or by The Wellcome
Trust Sanger Institute (Cambridge, United Kingdom). Clones lo-
calized on chromosome 22q12-q13.2 (CTA-415G2, LL22NCO1-
95B1, RP1-288L1, CTA-714B7, RP1-41P2, CTA-390B3, RP5-1177I5,
RP1-37E16, RP3-466N1, RP5-1014D13, RP5-1039K5, CTA-228A9,
CTA-447C4, RP1-5O6, RP3-434P1, RP1-319F24, RP3-508I1S, RP3-
327516, CTA-150C2, RP4, 742C19, and LL22NC03-10C3) were
directly labeled with Cy3. The control probes (RP1-41P2 and
RP1127L4) were directly labeled with fluorescein isothiocyanate,
and chromosomes were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). The specific signal intensity and its sub-
localization along the chromosome axis were analyzed using a
Leica fluorescence microscope equipped with the Visilog-6 pro-
gram (Noesis). On the basis of FISH results, additional QMF-PCR
primers were designed to delineate the extent of deletions. Po-
sitions and sequences of these additional primers are reported in
table 4.
Chromosome Segregation Analysis
Seven chromosome 22 microsatellites (D22S420, D22S539,
D22S315, D22S280, D22S283, D22S423, and D22S274) were an-
alyzed in patient 3 and his parents, with use of the linkage map-
ping set (Applied Biosystems) in accordance with the manufac-
turer’s instructions.
SOX10 Point-Mutation Screening in Patients with WS2
In the absence of a full description of the 5′ UTR noncoding
exon(s) of SOX10, we used, for convenience, the exon-numbering
system used elsewhere—that is, noncoding exons 1 and 2, the
ATG codon in exon 3, and the stop codon in exon 5.18 Three sets
of primers were used to amplify the SOX10 gene fragments cov-
ering coding exons 3–5 and intron-exon boundaries (first set:
exon 3, forward 5′-ACCCACCTAGAGTCTGGCATG-3′ and reverse
5′-CTCGGCTACCCTGAATCCAC-3′, 733-bp PCR product; second
set: exon 4, forward 5′-CCACAAATCATAGGGCACAG-3′ and re-
verse 5′-TAGAGTCCAGGGTCTCATTG-3′, 523-bp PCR product;
third set: exon 5, forward 5′-CCTGCCTCTAACCTGCTTCC-3′ and
reverse 5′-ACCTCCTTCTCCTCTGTCCA-3′, 997-bp PCR product).
The PCR covering the exon 3 region contained 10% DMSO. Re-
sulting PCR products were sequenced using a 16-capillary ABI
Prism sequencer and the Terminator Cycle Sequencing kit. Ad-
ditional internal sequencing primers were used for exon 3 (for-
ward 5′-GCGAGCTGGGCAAGGTCAAG-3′ and reverse 5′-TCGCC-
GTCCTGCTGCTCCTT-3′) and for exon 5 (forward 5′-GGATGCC-
AAAGCCCAGGTGA-3′ and reverse 5′-GTAGGCGATCTGTGAGG-
TGG-3′).
Plasmids, Cell Culture, Transfection, and Reporter Assays
The pECE-SOX10, pECE-SOX10-E189X, pECE-SOX10-Y313X,pECE-
SOX10-482ins6, pECE-PAX3, pECE-EGR2, pGL3-MITFdel1718,
and pGL3-Cx32 vectors were described elsewhere.30,43 The
p.Val92Leu mutation (named “V92L” for convenience) was in-
troduced within the pECE-SOX10 construct by site-directed mu-
tagenesis with use of the QuikChange Mutagenesis Kit (Strata-
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Table 4. Additional QMF-PCR Primers, Ordered Centromeric to
Telomeric
Gene Position
Primer Sequence
(5′r3′)
Forward Reverse
FBX07 exon 1 CGCCTCAGCTACCCCTCAGC CCGGCCCCAGCGTACCTGTA
TIMP3 exon 1 CTGGAGGGGTAGCAGTTAGC GATCGTTCAGATCCTTATAG
ISX exon 1 GATCAACAACTGTCAGCTCC CCTGCAGGTGGAGGCTGAGG
TOM1 exon 1 CGGTAGCAGCAATGGACTTT TCCTTACCTACTGGCTGTCA
APOL3 exon 4 TTCAGGCATCTTCCTTGCAC AAGTCACTAACACTCAGCTC
MYH9 intron 1 AGGCGGCTGTCTCCACCGGG GAGTGATTGTCTCAAAAGGC
CACNG2 exon 1 CACACTCTCCCGAGAACCAG CAAGTACCTTCTAGGCAGCA
LGALS2 exon 4 GAGAGCCTGGCCTGGACACA GAAAGAGGACATGTTGAACC
SH3BP1 exon 10 TGTGACGGATGATTTCAGAT ATGCCCTCAGAAAGCAGCAT
TRIOBP exon 1 GGTGAAATTCCTCAGCTCTC GTATCTTACTTGTGCAAGGG
MICALL1 exon 8 CCCATGGATCACGCTGGTGC TAGGGGTGATGCCGTACCAG
MICALL1 intron 9 TATAATGTACATGCTGCTGT GTACTGAGCCCAGGCAATCC
MICALL1 exons 11–12 GACATCCATGGAGAGATGGA GAGCTCGGACTCTCGCCGCA
MICALL1 exon 16 GGCAGCGGTGATTCAGCCCT ACTGAGATCCAAGGGCGCCT
C22ORF23 exon 4 GATGCTTTGCCCCTACAGTG GCTGAGGCTCAAGAGCATTG
C22ORF23 exon 3 CAGAGGGCAGAAATTTTATT CATGATGTCCATGATGTGGC
POLR2F exon 1 CAGTCAGCGCATGCGCACTT CAGACATTGCCCCTAGACGC
P2_3-4 20540/20829 CAGAGGTAATCAAGTTAGCC GTATTAGGATGGGTCGTAGG
P2_3-3 21390/21739 CACCTGGCCAGGATGAGCTT CCACAGTGAGCACTCAGGAA
P2_3-2 23920/24166 TTGTAAAGCAACAGAGGAGC CCTTCCGCAAAGACTTGCTG
P2_3-1 31482/31759 CCAAAAGCAGAAATCTGGGA GGCCTGAGGCTCCAGCTGAG
PLA2G6 exon 7 GATGGGATGGGAGGCAGTCT CCGTGGGTCAGCAGCACTAT
PLA2G6 exon 4 GGCGGGAATGCTCTTGAGCT CACCCTGGACAGCATAATGG
PLA2G6 intron 2 GGCTTCAGGAGGGCAGAGCA CCAGGGCTTTTAACATACCA
PLA2G6 exon 2 CCTTCAGTGGCGTCACCAAC GGTCCAAGAGTACAGTCTCC
C22ORF5 exon 9 CTCTAGACCTGGGGCCTCCG ATGCAGGCCTCTGCCACGAG
KDELR3 exon 1 TGGACCATGAACGTGTTCCG ATCATCTCGAGGGGTCCTCC
DDX17 exon 1 TTGTGCAGTCGCTGGGAAGG GATAGAGATCTGGGAGCGGG
CBX7 intron 1 TCCTACCCCATCTGCCTTCT CCTGGAGCCTCCCAAAGGGC
PDGFB exon 7 AGCCTGTGGCTTGGAGTGGC GTGGGAGCTCAGATCCCACC
NOTE.—The positions of primers P2_3-1 to P2_3-4, located between P2 and P3
(see table 2), are given with the A of the SOX10 ATG numbered as 1. NCBI build
36.2 was used. The GenBank accession number for all primers is NC_000022.9.
gene). Luciferase assays and immunofluorescence experiments
were performed 24 h after transfection of HeLa cells, as described
elsewhere.30,43,63 The SOX10 antibody used for immunofluoresc-
ence experiments was described elsewhere.64 The P0 construct was
kindly provided by M. Wegner.29
Results
Identification of SOX10 Deletions in Patients Presenting
with WS4 or PCWH
In our experience, ∼20%–40% of affected individuals
with the WS4 or PCWH phenotypes have no mutations
within SOX10, EDN3, or EDNRB identifiable by conven-
tional genetic analysis with the use of DNA sequencing
of PCR-amplified gene segments. Since this technique
does not detect heterozygous deletions, we decided to
search for SOX10 deletions or rearrangements by QMF-
PCR. Our study included 29 patients presenting with the
classic form of WS4 or PCWH, previously found to be
negative for SOX10, EDN3, and EDNRB point mutations.
We first analyzed the three coding exons of SOX10, part
of the POLR2F downstream gene, and sequences located
up to 50 kb upstream of SOX10 (S1–S4) (see fig. 1A). One
of them, S1, was described elsewhere as a SOX10 en-
hancer65 (see table 2 for sequences of primers P1–P9).
We identified two heterozygous deletions (patients 1
and 2; see the “Subjects” section and table 1 for clinical
descriptions). The first, found in a patient presenting with
a classic WS4 phenotype, removes part of exon 5 (fig. 1A,
patient 1). PCR amplification with the use of primers lo-
cated in intron 4 and exon 5 and cloning and sequencing
of the resulting products revealed a complex rearrange-
ment combining a 1,128-bp deletion, encompassing 740
bp of intron 4 and 388 bp of exon 5, and a 3-bp insertion
(fig. 1B). The other deletion, found in a patient with
PCWH, includes the whole SOX10 gene, POLR2F, and the
upstream S4 sequence (fig. 1A, patient 2). FISH analysis
with use of a BAC encompassing the whole region (clone
RP5-1039K5) (fig. 1A) confirmed the QMF-PCR results. In-
deed, we observed a significantly decreased signal on one
of the chromosomes 22 in all the metaphases (fig. 1C,
patient 2), showing that the deletion removes only part
of the RP5-1039K5 probe (S1–S3 are not deleted) (see fig.
1A). In each of the two cases, the analysis of parent DNA
Figure 1. SOX10 deletions in patients presenting with the classic form of WS4 or PCWH. A, Schematic representation of the three
deletions identified by QMF-PCR. The scheme on the top indicates the SOX10 gene structure (an approximate scale is shown on the
right). SOX10 coding sequence (exons 3–5) is indicated with black boxes, and noncoding exonic sequence is indicated with white
boxes. Arrowheads indicate the position of the segments analyzed by QMF-PCR (P1–P9; see table 2 for corresponding primer sequences).
They include the downstream adjacent POLR2F gene (gray box) and four short regions located up to 50 kb upstream of SOX10, indicated
by dark lines and labeled S1–S4. QMF-PCR results for patients 1–3 are indicated:  p not deleted;  p deleted. The phenotypes are
indicated on the left. B, Schematic representation (top) and electropherogram (bottom) of the deletion breakpoint region of patient
1. The size of the deletion and the nucleotidic localization of the breakpoint are indicated on the diagram. The 3 inserted nt are boxed.
C, Hybridization pattern of patients 2 and 3 with use of BAC clone RP5-1039K5 encompassing the SOX10 locus (indicated at the top
of panel A). The BAC clone RP5-1039K5 is shown in red, and the control probe (RP1-41P2) is shown in green. The normal chromosome
22 is indicated by an arrow, and the deleted chromosome 22 is indicated by an arrowhead.
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Figure 2. Functional consequences of the p.Val92Leu (V92L) mutation. A, Amino acid sequence comparison of the region immediately
preceding the HMG domain of SOX10 proteins across evolution and of SOX subgroup E proteins (human sequences). Gaps are indicated
by blanks. The first part of the HMG domain is boxed, and the amino acid substitution V92L from patient 3 is indicated by an arrow.
SOX10 sequence reference numbers: human (accession number NP_008872.1), mouse (XP_128139.4), chicken (NP_990123.1), fugu
(NP_001072112.1), zebrafish (NP_571950.1), human SOX8 (NP_055402.2), and human SOX9 (NP_000337.1). B, Subcellular localization
of wild-type SOX10 and p.Val92Leu mutant. HeLa cells were transfected with pECE-SOX10 (WT) or mutant (V92L) constructs for 24 h,
were fixed, and were immunostained for SOX10. Cultures were counterstained with DAPI. C and D, Transactivation capacities of SOX10
proteins. The MITF promoter (pMITF) (C) or the GJB1 (pCx32) promoter (D) luciferase reporters were transfected in Hela cells in combination
with wild-type (WT) or mutant SOX10 proteins (V92L, E189X, 482ins6, and Y313X), and/or PAX3 (C) or EGR2 (D). Reporter-gene activations
are presented as fold induction relative to the empty expression vector (pECE). Results represent the meanSEM from six experiments,
each performed in duplicate. Insets in C and D show a schematic representation of relative localization of SOX10 (white boxes), PAX3
(striped circles) or EGR2 (striped triangles) binding sites on MITF or GJB1 (Cx32) promoters.
by QMF-PCR revealed the de novo occurrence of the de-
letion (table 1).
Detection of a SOX10 Deletion in a Patient with PCWH
with p.Val92Leu Variation
Sequencing of the SOX10 coding exons and intron-exon
boundaries in newly recruited patients led us to identify
a new point mutation (nucleotide substitution c. 274GrC
in exon 3) that predicts the replacement of a valine by a
leucine at codon 92 (p.Val92Leu) in a patient presenting
with PCWH (patient 3) (see the “Subjects” section and
table 1 for clinical description). This amino acid substi-
tution affects a residue located within a region directly
preceding the HMG domain that is well conserved not
only between SOX10 proteins across evolution but also
among the SOX E members, SOX8 and SOX9 (fig. 2A).28
Surprisingly, this variation was observed at the homozy-
gous state and therefore contrasts with the heterozygous
state of all the mutations identified to date. The parents
were not consanguineous and did not present any feature
of the disease, except for early graying hair in the mother.
We found the mutation at the heterozygous state in the
father’s DNA only. The analysis of seven chromosome 22
microsatellites excluded a chromosome segregation ab-
normality and the possibility of a chromosome 22 pater-
nal isodisomy (data not shown).
To explain these data, we searched for a deletion or re-
arrangement of SOX10 that would result in a hemizy-
gous p.Val92Leu mutation. QMF-PCR experiments in-
deed unraveled a deletion that removes the whole SOX10
gene, along with the upstream and downstream sequences
tested (fig. 1A, patient 3). FISH analysis with use of the
BAC clone RP5-1039K5 confirmed the presence of a de-
letion encompassing the whole region (fig. 1C, patient 3,
showing presence of only one signal on the normal chro-
mosome 22). Analysis of parent samples established the
de novo occurrence of the deletion (table 1).
These results suggested that the phenotype of patient 3
is related to this large deletion, but we could not exclude
the possibility that the p.Val92Leu variation contributes
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to the phenotype. To test this possibility, we introduced
the mutation into the SOX10 cDNA and analyzed its func-
tional consequences in vitro. Immunofluorescence exper-
iments on HeLa cells transiently transfected with wild-
type or p.Val92Leu constructs revealed correct nuclear
localization of the mutant protein (fig. 2B).
The region affected by the mutation was previously im-
plicated in DNA-dependent dimerization, both in SOX10
and SOX9.29,42,45,66 Moreover, a SOX9 mutation located in
the same region (p.Ala76Glu) was shown to selectively
abrogate DNA-dependent dimerization and to thus inter-
fere with promoter activation via natural target sites that
require binding of SOX9 as dimers.66 We therefore ana-
lyzed the transactivation potential of the p.Val92Leu mu-
tant on two promoters previously shown to contain mo-
nomeric or dimeric SOX10 binding sites—MITF and Cx32,
respectively. Indeed, SOX10, in synergy with PAX3, reg-
ulates MITF expression by directly binding to its promoter
as monomers.30,33 SOX10, on the other hand, regulates
GJB1 (encoding connexin 32 [Cx32]) expression by di-
rectly binding to its promoter on a dimeric configuration
and in synergy with its cofactor EGR243,67 (insets in fig.
2C and 2D). Cotransfection of either promoter with wild-
type or p.Val92Leu SOX10 mutant and/or SOX10 cofac-
tors (PAX3 and EGR2) revealed that normal and mutant
SOX10 have similar transactivation capacities on these
promoters, alone or in synergy with the cofactors (fig. 2C
and 2D). In contrast, three previously identified SOX10
mutations (p.Glu189X, c.482ins6, and p.Tyr313X, named
“E189X,” “482ins6,” and “Y313X,” respectively, in fig. 2C
and 2D) failed to transactivate these reporter constructs,
as described elsewhere.30,43,68 We also performed similar
experiments, using another SOX10-responsive promoter
known to contain SOX10 dimeric binding sites, P0, and
found no difference between wild-type and p.Val92Leu
mutant transactivation capacities (data not shown). There-
fore, the p.Val92Leu variation does not seem to affect
SOX10 function, at least in vitro, which argues in favor
of the deletion as the cause of the phenotype observed in
this patient.
Molecular Characterization of Large Deletions in Patients
with PCWH
To define the boundaries of the deletions encompassing
the SOX10 gene found in patients 2 and 3, we extended
our analysis to adjacent regions, using two complemen-
tary strategies: FISH and QMF-PCR. In the case of patient
2, we chose additional sets of QMF-PCR primers localized
between upstream S3 and S4 sequences, which allowed us
to map the telomeric border of the deletion to a region
located 24–31 kb upstream of the SOX10 start codon (fig.
3B, patient 2). In parallel, FISH experiments with the probe
RP5-1014D13 (covering regions proximal to POLR2F, in-
cluding MICAL-L1) (see fig. 3) showed a distinct signal on
both chromosomes 22, positioning the centromeric bor-
der of the deletion between POLR2F and MICAL-L1 (fig.
3A). We chose additional sets of QMF-PCR primers within
the genes located in the region and localized the end of
the deletion between exons 3 and 4 of the C22ORF23 se-
quence (see fig. 3B and table 4 for corresponding pri-
mers). The whole deletion therefore encompasses 56–68
kb including, in addition to SOX10, POLR2F and part of
C22ORF23.
In the case of patient 3, we performed FISH analysis,
using RP5-1014D13 on one side and CTA-228A9 on the
other. This allowed us to localize the centromeric border
of the deletion between RP5-1014D13 (that shows hy-
bridization on both chromosomes 22) and RP5-1039K5
(that shows only one signal on normal chromosome 22)
(figs. 1C and 3A). The telomeric border was localized
within CTA-228A9 (we observed a significantly decreased
signal on one of the chromosomes 22 in all the meta-
phases) (fig. 3A). On the basis of these results, we repeated
a series of multiplex PCR, using primers located within
C22ORF23 or MICAL-L1 on one side and in PLA2G6 on
the other, and were able to finally determine the deletion
boundaries between intron 9 and exon 8 of MICAL-L1 and
between exon 4 and intron 2 of PLA2G6 (see fig. 3B and
table 4 for corresponding primers). The whole deletion
therefore encompasses 213–222 kb, including part of the
MICAL-L1 gene, the C22ORF23, POLR2F, SOX10, PICK1,
SLC16A8, and BAIAP2L2 genes, and part of the PLA2G6
gene.
Identification of SOX10 Deletions in Patients with WS2
WS4-affected patients with SOX10 point mutations or de-
letions exhibit a large variability and an incomplete pen-
etrance of each feature (i.e., fully blue irides, patchy blue
irides, or normal eyes; large, small, or no depigmented
skin patches; short- or long-segment Hirschsprung disease
or chronic intestinal pseudo-obstruction, etc.). Interest-
ingly, we previously described a c.1076delGA mutation in
a patient with a classic form of WS418 that was inherited
from a mother presenting with deafness and white fore-
lock only. We also described a p.Ser135Thr (S135T) mu-
tation in a patient presenting with a peculiar phenotype
named “Yemenite deaf-blind hypopigmentation syn-
drome” without any intestinal dysfunction.48 These two
phenotypes, which are reminiscent of that observed in
patients with WS2, prompted us to search for SOX10 de-
letions in unexplained cases of WS2. Screening of 30 cases
(previously found to be negative for MITF) by means of
QMF-PCR allowed us to identify five different SOX10 de-
letions (in patients 4–8) (see the “Subjects” section and
table 1 for clinical descriptions).
The first encompasses exon 3 (fig. 4A, patient 4). PCR
amplification with use of sets of primers located in exon
3 and intron 3, followed by cloning and sequencing of
the PCR products, revealed a 253-bp deletion that re-
moved 210 bp of exon 3 and 43 bp of intron 3 (fig. 4B).
Interestingly, the patient’s brother, who presented with
similar WS2 features, also carries the deletion (fig. 4B).
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Figure 3. Determination of the extent of large deletions in patients with PCWH. Schematic representation of the deletions in patients
2 and 3 was determined by FISH (A) or QMF-PCR (B). A, Representative FISH results. The names of the BACs used for hybridization are
indicated on each panel. B, Scheme with the names, positions, and orientation of genes located proximal or distal of SOX10. An
approximate scale is shown. BACs used for FISH experiments are shown on the left, and segments analyzed by QMF-PCR are indicated
by arrowheads (see table 4 for corresponding primer sequences). QMF-PCR results of patients 2 and 3 are indicated next to the
corresponding fragments:  p not deleted;  p deleted.
However, it was not found in the parents’ DNA, suggesting
germline mosaicism. We analyzed hair roots and buccal
and uroepithelial cell samples of both parents by PCR am-
plification and found the band specific to the deleted allele
in the mother’s uroepithelial cell sample, showing the ex-
istence of somatic mosaicism (fig. 4C and table 1).
The second deletion encompasses 1,777 bp and removes
the whole exon 4, 1,112 bp of intron 3, and 396 bp of
intron 4 (fig. 4A and 4D, patient 5). The father’s DNA was
not available. However, analysis of the mother’s DNA by
QMF-PCR and PCR sequencing techniques revealed that
the deletion is maternally inherited, in agreement with
the observation that the mother also presents with WS2
(fig. 4D and table 1).
The other three deletions included the whole SOX10
gene, as well as POLR2F and the upstream S4 sequence
(fig. 4A, patients 6, 7, and 8). Additionally, sequences S1–
S3 were deleted in patients 7 and 8. FISH analysis with
Figure 4. SOX10 deletions in patients presenting with WS2. A, Schematic representation of the five deletions identified by QMF-PCR.
The top scheme indicates the SOX10 gene structure and QMF-PCR experiment results ( p not deleted;  p deleted), as described
in figure 1. B and D, Schematic representation (top) and electropherograms (bottom) of the breakpoint deletion region of patient 4
(B) and patient 5 (D) and their relatives. The sizes of the deletions and the breakpoints are indicated on the scheme. C, PCR covering
exon 3 and intron-exon boundaries, with the use of DNA from patient 4, his brother, his mother, and his father, extracted from leukocytes
(L), buccal cells (B), uroepithelial cells (U), and hair roots (H). The normal band is indicated by an arrow, and the mutant allele is
indicated by an arrowhead. Note the faint mutant band in the mother’s uroepithelial cells. E, Representative FISH result obtained for
patient 8 with probe RP5-1039K5 encompassing the SOX10 locus (indicated on the top scheme of panel A). The BAC clone RP5-1039K5
is shown in red, and the control probe (RP1-127L4) is shown in green. The normal chromosome 22 is indicated by an arrow, and the
deleted chromosome 22 is indicated by an arrowhead.
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use of the BAC clone RP5-1039K5 confirmed the presence
of a deletion encompassing the whole region analyzed in
patient 8 (fig. 4A and 4E). Analysis of the parents’ samples
revealed the de novo occurrence of the deletions in these
three patients (table 1).
Molecular Characterization of Large Deletions in Patients
Presenting with WS2
To define the boundaries of the three deletions encom-
passing the whole SOX10 gene, we extended our analyses
to adjacent regions. In the absence of material with which
to perform FISH experiments in patients 6 and 7, we de-
termined the boundaries of the deletion by repeating
many sets of QMF-PCR (fig. 5B and data not shown). In
the case of patient 6, additional sets of QMF-PCR primers
between upstream S3 and S4 sequences allowed us to map
the telomeric border of the deletion to a region located
20–21 kb upstream of the SOX10 start codon. The centro-
meric border was localized between genes CACNG2 and
MYH9, therefore delimiting a deletion of 1.3–1.6 Mb that
removes at least 42 genes, including SOX10 and TRIOBP
(fig. 5B).
Patient 7′s deletion removes 574–898 kb. Indeed, bound-
aries were located between LGALS2 and SH3BP on one side
and C22ORF5 and KDELR3 on the other side. The dele-
tion therefore encompasses 23 genes, including SOX10,
TRIOBP, and PLA2G6 (fig. 5B).
In the case of patient 8, FISH analysis was performed
using several probes, including CTA-415G2, LL22NC01-
95B1, RP1-288L1, CTA-714B7, RP5-1177I5, RP1-37E16,
CTA-228A9, RP1-5O6, RP3-434P1, CTA-150C2, and RP4-
742C19. The telomeric border was localized within the
RP4-742C19 BAC (we observed a significantly decreased
signal on one of the chromosomes 22 in all the meta-
phases) (fig. 5A), and the last centromeric deleted BAC
was LL22NCO1-95B1 (fig. 5B and data not shown). QMF-
PCR with the use of primers within some of the genes
located in the region confirmed the results, therefore de-
limiting a deletion of 5.5–6.1 Mb encompassing 102 dif-
ferent genes, including SOX10, LARGE , RASD2, RBM9,
MYH9, CACNG2, TRIOBP, PLA2G6, KCNJ4, and NPTXR
(fig. 5B and data not shown).
The identification of five SOX10 deletions in the 30 cases
studied revealed that SOX10 is a new gene of WS2 and
thus prompted us to screen for SOX10 point mutations.
However, we failed to detect any mutation by DNA se-
quencing of the three SOX10 coding exons. Taken to-
gether, these results make SOX10 the third gene discovered
to be involved in WS2, with an estimated frequency (15%)
similar to that of MITF.
Discussion
Considering our panel of patients presenting with WS4
(classic forms of WS4 and PCWH), we estimated that the
phenotype is caused, for 20%–30% of patients, by EDN3
or EDNRB point mutations and, for 40%–50% of patients,
by SOX10 point mutations. In patients with WS2, muta-
tions in the MITF gene were identified in ∼15% of cases.
Thus, 20%–40% of WS4 cases and 85% of WS2 cases re-
mained unexplained at the molecular level, raising the
possibility that other genes are involved or that some mu-
tations within the known genes are not detected by the
methods commonly used for genotyping. In this study,
we describe the first characterization of SOX10 deletions
in patients presenting with WS4 and WS2. We found three
deletions among 30 WS4 cases. Taking into account the
fact that we tested only DNA samples of patients negative
for SOX10, EDN3, and EDNRB point mutations, we esti-
mate that SOX10 deletions are involved in ∼5% of all cases
of WS4. We also found five deletions among 30 WS2 cases.
Since we tested only patients negative for MITF mutations,
we can estimate that SOX10 deletions account for ∼15%
of all WS2 cases. These results extend the spectrum of
SOX10 mutations found in patients with WS4 and make
SOX10 the third gene discovered to be involved in WS2,
with an estimated frequency similar to that of MITF. In
terms of molecular diagnosis, SOX10 deletions should now
be searched for when no SOX10 point mutations (PCWH)
or no SOX10, EDN3, and EDNRB point mutations (classic
form of WS4) are found. More importantly, SOX10 dele-
tions should be considered for first-step analysis in WS2,
as well as MITF mutations.
Full characterization of the eight deletions by PCR and
sequencing, or by a combination of QMF-PCR and FISH,
revealed eight different deletion events ranging from the
deletion of a single exon of SOX10 to the deletion of up
to 6 Mb around the SOX10 locus (table 1). Both intragenic
and full SOX10 deletions were observed in either WS2 or
WS4. Intragenic deletions involved different exons. The
observation of sequences surrounding the breakpoints of
the three intragenic deletions revealed no clear mecha-
nism except for in patient 5, in whom the deletion oc-
curred between two hexanucleotide repeats, tggtgg, re-
taining one copy. Bioinformatics analysis with the use of
Netgene2 and HMMgene software was performed to pre-
dict the functional consequences of these deletions. In the
case of patient 1, the rearrangement was predicted to ac-
tivate a cryptic splice-acceptor site within exon 5, located
downstream of the stop codon (780 nt after the usual
acceptor site; estimated frequency of 97%). The predicted
protein would lack the last 206 aa and would be replaced
by 27 unrelated aa, thereby removing the transactivation
domain. In the case of patient 4, the deletion removed
the exon 3–intron 3 boundary. In silico analysis revealed
that this deletion could result in translation of a short
intronic sequence with a nearby immediate stop codon
(5 aa downstream), with the resulting protein devoid of
all functional domains. Alternatively, the use of a cryptic
splice-donor site (estimated frequency 55% or 88%, de-
pending on the program used), located 55 nt downstream
of the missing donor site, could produce a protein lacking
69 aa, removing the dimerization domain and half of the
Figure 5. Determination of the extent of large deletions in WS2. Schematic representation of the deletions in patients 6, 7, and 8
was determined by FISH (A) or QMF-PCR (B), as described in figure 3. Only the first nondeleted or partially deleted BACs are shown in
panel A.
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HMG domain but leaving the transactivation domain in-
tact. In the case of patient 5, the Netgene2 software pre-
dicted that the deletion could lead to exon 4 skipping,
therefore resulting in a frameshift and a truncated protein
of 189 aa with 47 unrelated aa in the carboxyterminal
part. Half of the HMG domain and the following domains
would be removed. Unfortunately, there is no SOX10-ex-
pressing tissue easily accessible by noninvasive methods
in patients, which precludes analysis of the protein pro-
duced in vivo.
Most of the SOX10 disease-associated point mutations
identified so far, regardless of whether they cause WS4 or
PCWH, result in premature termination codons. An ex-
planation for the presence or absence of a neurological
phenotype (i.e., central or peripheral) that characterizes
the PCWH syndrome has been hypothesized to be related
to the NMD process.57 Truncating mutations located in
the first coding exons (exons 3 and 4) activate the NMD
RNA surveillance pathway, leading to haploinsufficiency
and classic forms of WS4. On the other hand, truncating
mutations located in the last coding exon (exon 5) escape
NMD, leading to translation of an abnormal SOX10 pro-
tein with a dominant negative effect and therefore re-
sulting in the more severe PCWH phenotype. Considering
the published18,47,49,50,52–58 and our unpublished cases with
SOX10 point mutations, we observed that the length of
intestinal aganglionosis may also fit the NMD hypothesis,
since all the point mutations associated with the long-
segment Hirschsprung disease are located in exon 5. Ac-
cordingly, full deletions of SOX10 would be expected to
cause classic forms of WS4 with short-segment Hirschs-
prung disease as a result of haploinsufficiency. All three
patients indeed present with a short form; however, two
of them have mild PCWH syndrome, an observation that
does not match the NMD hypothesis (table 1).
We wondered whether the PCWH syndrome might also
result from other mechanisms, at least in some of the
patients. Interestingly, one of the PCWH-affected patients
with a SOX10 deletion (patient 3) also carries a SOX10
valinerleucine substitution at the hemizygous state. This
variation, which could worsen the phenotype of the pa-
tient, is located in a highly conserved region crucial for
the mediation of DNA-dependent dimerization. We thus
reasoned that the p.Val92Leu variation, although not a
drastic substitution, might interfere with the formation of
SOX10 dimers and thus specifically hamper promoter ac-
tivation via natural target sites that require binding of
SOX10 dimers. We therefore compared wild-type and
p.Val92Leu SOX10 transactivation capacities on MITF
and GJB1 (Cx32) promoters containing monomeric or di-
meric binding sites, respectively, and found no differences.
These results suggest that the p.Val92Leu variation does
not affect SOX10 function, at least in vitro, arguing in
favor of the deletion as the major or sole cause of the
PCWH phenotype observed. A contiguous gene syndrome
may also account for the neurological features. The de-
letion identified in patient 3 encompasses the PLA2G6
gene known to be involved in a recessive neurological
defect (infantile neuroaxonal dystrophy 1, neurodegen-
eration with brain iron accumulation, and Karak syn-
drome).69 However, this gene is not deleted in patient 2,
who has a mild PCWH syndrome resembling that of pa-
tient 3, suggesting that the heterozygous PLA2G6 dele-
tion is not involved in the phenotypic expression of the
disease.
In WS2, as in WS4, the largest deletions are found in
patients presenting with additional symptoms, suggesting
that some features may be influenced by the presence of
other genes. Indeed, several genes removed by one or
more of the deletions have a well-established neurological
role (i.e., LARGE, RASD2, RBM9, CACNG2, KCNJ4, and
NPTXR). Two genes involved in human hearing loss are
also located within some of the deleted regions: TRIOBP
(recessive nonsyndromic deafness [DFNB28]70) and MYH9
(Epstein and Fechtner syndromes and dominant pro-
gressive isolated deafness [DFNA17]71,72). However, when
comparing all eight patients, we observed no clear cor-
relation between the deletion of one of these genes and
the presence of neurological features or the deafness phe-
notype. In fact, as for SOX10 point mutations, SOX10 de-
letions by themselves might be sufficient to explain the
phenotypes observed. On the other hand, the autism of
patient 7 and the cardiac defects of patient 8 have not
previously been linked to SOX10 mutations and may re-
sult from the deletion of additional genes. We found no
evidence of a known gene removed by the deletion in
patient 8, which could explain the cardiopathy, but this
deletion encompasses 102 genes, and they are not all
functionally characterized. In autism, recurrent deletions
of chromosome 22q13 have been characterized,73 includ-
ing a frequent breakpoint within the SHANK3 gene.74
However, this region is distal to the deletion found in
patient 7. The question of whether the association with
autism in patient 7 is fortuitous or results from the de-
letion remains unanswered.
The WS subtypes were initially clinically defined. It ap-
pears, however, that this classification does not reflect the
molecular mechanisms. Indeed, an overlap between WS1
and WS3 has already been reported, and we now report
an overlap between WS2 and WS4. In developmental syn-
dromes, incomplete penetrance of some features is com-
monly observed. Incomplete penetrance of Hirschsprung
disease is described both in isolated and in syndromic
forms of the disease, and it may result from different
mechanisms, including genetic modifiers.75,76 In the case
of WS, incomplete penetrance of Hirschsprung disease
could explain the overlap between WS2 and WS4. How-
ever, with regard to this hypothesis, it is surprising to not
find SOX10 point mutations in WS2. To our knowledge,
no genetic disorder has been described to result exclu-
sively from deletions of the causative gene. It is possible
that the penetrance of one feature varies between dele-
tions and truncating point mutations, as shown, for ex-
ample, in Von Hippel–Lindau disease.77 In our case, in-
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complete phenotypic penetrance may be explained by
tissue-specific compensation of the loss of SOX10 by other
SOX proteins having partly redundant function, such as
SOX8 and SOX9. Interestingly, in mice that expressed
SOX8 instead of SOX10, the enteric defect was partially
or totally rescued in homozygotes or heterozygotes, re-
spectively, whereas the pigmentation defect was not.78 As
a result, SOX10 haploinsufficiency may be compensated
by SOX8 or SOX9 during enteric nervous-system devel-
opment, explaining the low penetrance of Hirschsprung
disease associated with SOX10 deletions (leading to WS2
or WS4). In contrast, the presence of a truncated SOX10
protein may impair SOX8 or SOX9 function, resulting in
a fully penetrant enteric phenotype (leading to WS4 on-
ly). However, it is possible that screening larger numbers
of patients with WS2 will result in the identification of
SOX10 point mutations.
An increasing diversity of clinical features is reported in
WS; some patients with WS4 present with pseudo-obstruc-
tion instead of Hirschsprung disease, and others present
with myelination defects of the peripheral nervous system
and CNS (i.e., PCWH syndrome). In this study, patients 7
and 8 presented with WS2 and central and peripheral neu-
rological features typical of PCWH—formally, a new syn-
drome indicating a continuum from isolated WS2 to se-
vere PCWH. On the basis of our observation of SOX10
deletions in WS2, it appears possible that EDN3 and
EDNRB mutations also play a role in WS2. Indeed, in a
subset of WS4-affected families with EDN3 or EDNRB
point mutations, heterozygous relatives present with a di-
versity of features that may occasionally recall WS2. It
therefore appears necessary to undertake a more complete
molecular analysis (including not only point mutations
but also deletions) of all the genes involved in WS2 or
WS4 (i.e., MITF, EDN3, and EDNRB). These comprehensive
studies are necessary to fully document the molecular
complexity and close relationship that link the different
subtypes of WS and to reappraise their current clinical
classification.
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